CareDx provides the following:
- AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients
- AlloMap Heart, a gene expression solution for heart transplant patients
- AlloSure Heart, a dd-cfDNA solution for heart transplant patients
- AlloSure Lung, a dd-cfDNA solution for lung transplant patients
It also offers the following:
- Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence-specific primer technology
- QTYPE, which enables precision in HLA typing
- Ottr, a transplant patient management software
- AlloSeq Tx, a high-resolution HLA typing solution
- AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood
- AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients
- XynQAPI, offering transplant quality tracking and waitlist management solutions
- AlloCare, a mobile app that offers a patient-centric resource for transplant recipients
CareDx offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina for the distribution, development and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss.
Goldman Sachs has a $13 target price, while the consensus target is $12.80. CareDx stock traded on Friday at $8.15.
Compass Pathways
Cathie Woods owns approximately 2.4 million shares, and this stock could have the biggest upside potential of all of these red-hot stocks. Compass Pathways PLC (NASDAQ: CMPS) operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase 3 clinical trials for the treatment of treatment-resistant depression, and it is in Phase 2 clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
The company announced earlier this month that the U.S. Patent Trial and Appeal Board reaffirmed decisions to uphold ‘257 Patent and ‘259 Patent, key patents covering COMP360 crystalline psilocybin polymorph A, the polymorph being used in the company’s Phase 3 clinical trials.
The Oppenheimer target price is $33, and Compass Pathways stock has a consensus target of $42.30. The shares traded at $7.85 on Friday.
Genius Sports
Cathie Wood owns over 5 million shares of this sports-betting-related stock, which has been hammered and holds massive upside potential, and it could even be a takeover target. Genius Sports Ltd. (NYSE: GENI) develops and sells technology-led products and services to the sports, sports betting and sports media industries.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
